Johnson & Johnson (JNJ): Rep. Thomas H. Kean Jr. (NJ07) disclosed a partial sale $1K–$15K
Rep. Thomas H. Kean Jr. (NJ07) disclosed a partial sale of Johnson & Johnson in the $1K–$15K range.
- $1,001–$15,000
- Reported range · official band, not an exact amount
- 23 days
- Disclosure lag
- Traded
- Oct 27, 2026
- Disclosed
- Nov 19, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Apr 10, 2026Federal contract · $198K obligatedDepartment of Defense awarded Johnson & Johnson: $198K obligated to date
- Jul 7, 2026Federal contract · $168K obligatedDepartment of Defense awarded Johnson & Johnson: $168K obligated to date
- Jul 30, 2026Federal contract · $385K obligatedDepartment of Veterans Affairs awarded Johnson & Johnson: $385K obligated to date
- Aug 20, 2026CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
- Aug 27, 2026CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
- Aug 28, 2026FDAFDA drug approval: Stelara
- Sep 2, 2026Federal contract · $385K obligatedDepartment of Veterans Affairs awarded Johnson & Johnson: $385K obligated to date
- Sep 2, 2026Insider · 1 personInsiders: 2 sales (~$9.2M)
- Sep 4, 2026FDAFDA device clearance: ATTUNE Revision Knee System
- Sep 8, 2026FDARecall: PERMA-HAND Silk Black Braided Sterile Nonabsorbable Surgical Suture, 1X18" TF-5, Product Code: N271H
- Sep 8, 2026CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
- Sep 17, 2026FDAFDA device clearance: HARMONIC 1100 Shears (HAR1120); HARMONIC 1100 Shears (HAR1136)
- Sep 18, 2026FDARecall: Automated Impella Controller, Packaged. Primary user control interface for the Impella Catheter, catheter-based heart pump.
- Sep 18, 2026FDARecall: Impella Optical Controller, Packaged. Primary user control interface for the Impella Catheter, a catheter-based heart pump.
- Sep 18, 2026FDARecall: Impella Connect Optical AIC, Packaged. Primary user control interface for the Impella Catheter, a catheter-based heart pump.
- Sep 23, 2026FDARecall: ETHILON Nylon Suture, Product Code 697G
- Sep 30, 2026CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
- Oct 5, 2026Federal contract · $385K obligatedDepartment of Veterans Affairs awarded Johnson & Johnson: $385K obligated to date
- Oct 13, 2026Company filing · Form 8-K · ResultsReported its results
- Oct 27, 2026 · this disclosureCongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
What came next
How to read House Clerk periodic transaction report
The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.
Full guide: What is the STOCK Act?
What else is on file for Johnson & Johnson
For Johnson & Johnson, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 4 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.
Other recent filings by Rep. Thomas H. Kean Jr. (NJ07)
- House Clerk periodic transaction report at Abbott Laboratories (ABT)Oct 30, 2026
- House Clerk periodic transaction report at ESAB (ESAB)Oct 30, 2026
- House Clerk periodic transaction report at Johnson & Johnson (JNJ)Oct 30, 2026
- House Clerk periodic transaction report at Mondelez International (MDLZ)Oct 30, 2026
- House Clerk periodic transaction report at Stryker Corporation (SYK)Oct 30, 2026
The full history of Rep. Thomas H. Kean Jr. (NJ07) is on the profile page.
How this filing works
Explore the data
Common questions
Which member of Congress traded Johnson & Johnson (JNJ) stock, and how much?
Rep. Thomas H. Kean Jr. (NJ07) disclosed a partial sale of Johnson & Johnson in the $1K–$15K range. Reported range, not an exact amount.
When did it happen, and when was it made public?
Traded: Oct 27, 2026. Disclosed: Nov 19, 2026. That is 23 days between the two dates.
Why is the amount a range and not an exact figure?
Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.
Where does this information come from?
From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Johnson & Johnson recently?
For Johnson & Johnson, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 4 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days. They are listed on the JNJ page.
Does this mean JNJ stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Johnson & Johnson
- SEC Form 13F-HRNov 16, 2026
- SEC Form 4Nov 13, 2026
- USAspending.gov award recordNov 13, 2026
- SEC Form 144Nov 12, 2026
- House Clerk periodic transaction reportOct 30, 2026
- House Clerk periodic transaction reportOct 5, 2026
Everything OQRO holds on this company is on its JNJ page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
